Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 36 results for deep brain stimulation

  1. Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache (HTG378)

    Evidence-based recommendations on implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache. This involves implanting a device into the cheek to stimulate a group of nerves called the sphenopalatine ganglion.

    HealthTech guidance
    Published
    26 June 2015
    View recommendations

    Sections for HTG378

  2. MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy (HTG541)

    Evidence-based recommendations on MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy in adults and children. This involves inserting a laser into the area of the brain causing seizures.

    HealthTech guidance
    Published
    4 March 2020
    View recommendations

    Sections for HTG541

  3. Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (HTG408)

    Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve to treat cluster headache and migraine in adults. This involves using a small handheld device to stimulate a nerve in the neck.

    HealthTech guidance
    Published
    23 March 2016
    View recommendations

    Sections for HTG408

  4. Transcranial magnetic stimulation for obsessive-compulsive disorder (HTG548)

    Evidence-based recommendations on transcranial magnetic stimulation for obsessive-compulsive disorder in adults. This involves pulsing electromagnetic energy through the skull to stimulate the brain.

    HealthTech guidance
    Published
    5 August 2020
    View recommendations

    Sections for HTG548

  5. Transcranial magnetic stimulation for auditory hallucinations (HTG555)

    Evidence-based recommendations on transcranial magnetic stimulation for auditory hallucinations. This involves stimulating the brain with pulses of electromagnetic energy.

    HealthTech guidance
    Published
    23 September 2020
    View recommendations

    Sections for HTG555

  6. Further research should describe patient selection and clearly define the target area of the brain. Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction in concomitant medication and hospital admissions.

    should describe patient selection and clearly define the target area of the brain. Outcomes should include reduction in seizure...

    Research recommendation
    Published
    26 October 2020

  7. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

    NICE guideline
    Published
    22 June 2022
    View recommendations

    Sections for NG220

  8. Devices for remote monitoring of Parkinson's disease (HTG657)

    Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease.

    HealthTech guidance
    Last updated
    25 January 2024
    View recommendations

    Sections for HTG657

  9. Deep brain stimulation for refractory epilepsy (IPG416)

    This guidance has been updated and replaced by NICE HealthTech guidance 550.

    Withdrawn guidance

  10. Deep brain stimulation for Parkinson's disease (IPG19)

    We have moved interventional procedures guidance 19 to become HealthTech guidance 7. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Deep brain stimulation for refractory epilepsy in adults (IPG678)

    We have moved interventional procedures guidance 678 to become HealthTech guidance 550. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Deep brain stimulation for intractable trigeminal autonomic cephalalgias (IPG381)

    We have moved interventional procedures guidance 381 to become HealthTech guidance 252. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)

    We have moved interventional procedures guidance 188 to become HealthTech guidance 122. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Deep brain stimulation for refractory chronic pain syndromes (excluding headache) (IPG382)

    We have moved interventional procedures guidance 382 to become HealthTech guidance 253. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. 24/7 EEG SubQ for epilepsy (MIB277)

    NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .

    Medtech innovation briefing
    Published
    2 November 2021